Inflammatory bowel disease (IBD) Task Force

Chairs: Mark Daly (FinnGen), Jukka Koskela (FinnGen), Amy Hart (J&J)

Secretary: Elisa Lahtela (FinnGen)

Main scientific questions

  • Can we define the genetics of disease progression?

    • Create definitions of progression (also severity, remission, therapeutic response) using hard endpoints of surgery and hospitalization as well as disease behavior, quantitative clinical biomarkers (Fcal, CRP, …), medication switching, etc.

    • Perform GWAS and compare genetics of progression to the established genetics of incidence

  • Can we use proteomics to define medication and progression signatures?

    • Using definitions defined in aim 1

    • Collect multiple time points at/before diagnosis and during disease progression

All Task Force related summary statistics can be found from: /finngen/library-green/task_force/

All Task Force GWASes can be found from Task Force PheWeb: https://results.taskforce.finngen.fi/arrow-up-right

More detailed Scientific proposal, meeting materials and analysis documentation can be found in Teams herearrow-up-right

How do I join the FinnGen Teams group?chevron-right

If you don't have access to the Teams Group, write to [email protected].

Last updated

Was this helpful?